About: Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19
Creator	Pastores, Stephen Daniyan, Anthony Devlin, Sean Korde, Neha Patel, Dhwani Scordo, Michael Vardhana, Santosha Foote, Michael Horwitz, Steven Jee, Justin Lumish, Melissa Narendra, Varun Nguyentran, Teresa Stonestrom, Aaron Wills, Beatriz
Source	MedRxiv
abstract	Background Corticosteroids, anti-CD20 agents, immunotherapies, and cytotoxic chemotherapy are commonly used in the treatment of patients with cancer. How these agents impact patients with cancer who are infected with SARS-CoV-2 remains unclear. Methods We retrospectively investigated associations between SARS-CoV-2-associated respiratory failure or death with receipt of the aforementioned medications and with pre-COVID-19 neutropenia. The study included all cancer patients diagnosed with SARS-CoV-2 at Memorial Sloan Kettering Cancer Center until June 2, 2020 (N=820). We controlled for cancer-related characteristics known to predispose to worse COVID-19. To address that more acutely ill patients receive therapeutic corticosteroids, we examined patient subsets based on different levels of respiratory support: <=2 L/min supplemental oxygen, >2L/min supplemental oxygen, and advanced respiratory support prior to death. Results Corticosteroid administration was associated with worse outcomes in the pre-2L supplemental oxygen cohort; no statistically significant difference was observed in the >2L/min supplemental oxygen and post-critical cohorts. Interleukin-6 (IL-6) and C-reactive protein (CRP) levels were lower, and ferritin levels were higher, after corticosteroid administration. In patients with metastatic thoracic cancer, 9 of 25 (36%) and 10 of 31 (32%) had respiratory failure or death among those who did and did not receive immunotherapy, respectively. Seven of 23 (30%) and 52 of 187 (28%) patients with hematologic cancer had respiratory failure or death among those who did and did not receive anti-CD20 therapy, respectively. Chemotherapy itself was not associated with worse outcomes, but pre-COVID-19 neutropenia was associated with worse COVID-19 course. Relative prevalence of chemotherapy-associated neutropenia in previous studies may account for different conclusions regarding the risks of chemotherapy in patients with COVID-19. In the absence of prospective studies and evidence-based guidelines, our data may aid providers looking to assess the risks and benefits of these agents in caring for cancer patients in the COVID-19 era.
has issue date	2020-08-12(xsd:dateTime)
bibo:doi	10.1101/2020.08.11.20145458
has license	medrxiv
sha1sum (hex)	cb4144d3fb1fbc1e1df0f78e7b7e3df5ac1cecf4
schema:url	https://doi.org/10.1101/2020.08.11.20145458
resource representing a document's title	Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19
resource representing a document's body	covid:cb4144d3fb1fbc1e1df0f78e7b7e3df5ac1cecf4#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'Patients' named entity 'CD20' named entity 'chemotherapy' named entity 'How' named entity 'commonly' named entity 'anti-CD20' named entity 'Immunomodulatory' named entity 'supplemental oxygen' named entity 'preprint' named entity 'corticosteroid' named entity 'cytotoxic chemotherapy' named entity 'malignancy' named entity 'Immunotherapy' named entity 'virus' named entity 'assay' named entity 'corticosteroid' named entity 'supportive care' named entity 'preprint' named entity 'corticosteroid' named entity 'peer review' named entity 'neutropenia' named entity 'supplemental oxygen' named entity 'medRxiv' named entity 'COVID' named entity 'medRxiv' named entity 'neutropenia' named entity 'hematologic malignancy' named entity 'hematologic cancer' named entity 'CTLA-4' named entity 'infection' named entity 'medRxiv' named entity 'World Health Organization' named entity 'adverse events' named entity 'corticosteroid' named entity 'corticosteroid' named entity 'preprint' named entity 'peer review' named entity 'peer review' named entity 'respiratory failure' named entity 'Wilcoxon signed-rank test' named entity 'confidence intervals' named entity 'COVID' named entity 'corticosteroids' named entity 'medRxiv' named entity 'hematologic cancer' named entity 'SARS-CoV-2' named entity 'neutropenia' named entity 'immunotherapy' named entity 'immunosuppression' named entity 'COVID-19' named entity 'metastatic disease' named entity 'immunomodulatory' named entity 'CRP' named entity 'thoracic cancer' named entity 'respiratory failure' named entity 'COVID' named entity 'preprint' named entity 'medRxiv' named entity 'peer review' named entity 'preprint' named entity 'corticosteroids' named entity 'IL-6' named entity 'neutropenia' named entity 'neutropenic' named entity 'neutropenia' named entity 'dependent variable' named entity 'respiratory support' named entity 'respiratory failure' named entity 'IL-6' named entity 'ferritin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software